期刊文献+

美罗培南治疗新生儿脓毒症的临床实践指南(2024年版)

Clinical practice guidelines for meropenem therapy in neonatal sepsis(2024)
下载PDF
导出
摘要 美罗培南是新生儿脓毒症治疗中使用最为广泛的特殊级别抗菌药物之一,但其不合理应用导致细菌多重耐药问题日益严峻。该指南遵循规范的制订方法与流程,针对9个临床问题形成了12条推荐意见,内容涵盖新生儿美罗培南的使用时机、推荐剂量、延长输注、监测与评估、抗菌药物调整方案、治疗疗程以及碳青霉烯耐药肠杆菌目细菌感染的治疗策略,以期为美罗培南在新生儿脓毒症患儿中的合理使用提供循证证据与用药建议。 Meropenem is one of the most widely used special-grade antimicrobial agents in the treatment of neonatal sepsis.However,its irrational use has led to an increasingly severe problem of bacterial multidrug resistance.The guideline was developed following standardized methods and procedures,and provides 12 recommendations specifically addressing 9 clinical issues.The recommendations cover various aspects of meropenem use in neonates,including timing of administration,recommended dosage,extended infusion,monitoring and assessment,antimicrobial adjustment strategies,treatment duration,and treatment strategies for carbapenem-resistant Enterobacteriaceae infections.The aim of the guideline is to provide evidence-based recommendations and guidance for the rational use of meropenem in neonates with sepsis.
作者 《美罗培南治疗新生儿脓毒症的临床实践指南》制订组 北京大学第三医院 《中国当代儿科杂志》编辑部 童笑梅 周文浩 杨克虎 周鹏翔 邢燕 Guideline Development Group of Clinical Practice Guidelines for Meropenem Therapy in Neonatal Sepsis;Peking University Third Hospital;Editorial Department of Chinese Journal of Contemporary Pediatrics;Tong X-M;Zhou W-H;Yang K-H
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2024年第2期107-117,共11页 Chinese Journal of Contemporary Pediatrics
基金 国家重点研发计划(2021YFC2700700) 国家自然科学基金项目(72304008)。
关键词 美罗培南 脓毒症 指南 新生儿 Meropenem Sepsis Clinical practice guideline Neonate
  • 相关文献

参考文献17

二级参考文献111

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:230
  • 2<应用抗菌药物防治外科感染的指导意见>撰写协作组.应用抗菌药物防治外科感染的指导意见(草案)ⅩⅦ——骨和关节感染[J].中华外科杂志,2005,43(4):270-272. 被引量:42
  • 3莫海玲.4种碳青霉烯类抗生素的药理学特点及临床应用评价[J].中国医院用药评价与分析,2007,7(2):96-98. 被引量:10
  • 4Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health ServRes, 2004, 4(1): 38.
  • 5Lacchetti C, Guyatt G. Surprising results of randomized trials. In: Guyatt G, Drummond R, eds. Users' guides to the medical literature: a manual of evidence-based clinical practice. Chicago, IL: AMA Press, 2002.
  • 6American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med, 1992, 117(12): 1038-1041.
  • 7Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med, 2002, 137(4): 273-284.
  • 8Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998, 280(7): 605-613.
  • 9Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288(3): 321-333.
  • 10Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J ivied, 1991,324( 12 ): 781-788.

共引文献1165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部